Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.

ABSTRACT: B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early recurrence and metastasis. Enoblituzumab is a humanized, Fc-engineered, B7-H3-targeting antibody that mediates antibody-dependent cellular cytotoxicity. In this phase 2, biomarker-rich neoadjuvant trial, 32 biological males with operable intermediate to high-risk localized PCa were enrolled to evaluate the safety, anti-tumor activity and immunogenicity of enoblituzumab when given before prostatectomy. The coprimary outcomes were safety and undetectable prostate-specific antigen (PSA) level (PSA₀) 1 year postprostatectomy, and the aim was to obtain an estimate of PSA₀ with reasonable precision. The primary saf

SUBMITTER: Shenderov E 

PROVIDER: S-EPMC10921422 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature